Azurocidin/CAP37/HBP Recombinant Protein | CAP37/HBP recombinant protein

Recombinant Human Azurocidin/CAP37/HBP Protein (C-6His)

Cat. Num. AAA2552381

• Gene Names: AZU1; AZU; HBP; NAZC; hHBP; AZAMP; CAP37; HUMAZUR
• Purity: >95% as determined by reducing SDS-PAGE.
• Synonyms: Azurocidin/CAP37/HBP; Recombinant Human Azurocidin/CAP37/HBP Protein (C-6His); Azurocidin; Cationic Antimicrobial Protein CAP37; Heparin-Binding Protein; HBP; AZU1; CAP37/HBP recombinant protein

• Host: Human Cells
• Purity/Purification: >95% as determined by reducing SDS-PAGE.
• Form/Format: Lyophilized from a 0.2 mum filtered solution of 20mM HEPES, 150mM NaCl, pH 7.5.
• Sequence Positions: Ile27-Pro250
• Sequence Length: 251

• Species: Human
• Endotoxin: <1.0 EU per ug as determined by LAL test.
• Fusion Tag: C-6His
• Preparation and Storage: Lyophilized protein should be stored at < -20 degree C, though stable at room temperature for 3 weeks.; Reconstituted protein solution can be stored at 4-7 degree C for 2-7 days. Aliquots of reconstituted samples are stable at < -20 degree C for 3 months.

Related Product Information for CAP37/HBP recombinant protein

Azurocidin is an Azurophil granule antibiotic protein, with monocyte chemotactic and antibacterial activity. The Azurophil granules, specialized lysosomes of the neutrophil, contain at least 10 proteins implicated in the killing of microorganisms. Azurocidin is a member of the serine protease family that includes Cathepsin G, Neutrophil Elastase (NE), and Proteinase 3 (PR3), however, Azurocidin is not a serine proteinase since the active site serine and histidine residues are replaced. Human Azurocidin together with NE and PR3 are expressed coordinately and are packaged together into azurophil granules during neutrophil differentiation. Azurocidin has been identified as a modulator of endothelial permeability and an important multifunctional inflammatory mediator. Neutrophils arriving first at sites of inflammation release Azurocidin which acts in a paracrine fashion on endothelial cells causing the development of intercellular gaps and allowing leukocyte extravasation. Azurocidin thus be regarded as a reasonable therapeutic target for a variety of inflammatory disease conditions.

NCBI and Uniprot Product Information

• NCBI GI #: 11342670
• NCBI GeneID: 566
• NCBI Accession #: NP_001691.1
• NCBI GenBank Nucleotide #: NM_001700.4
• UniProt Accession #: P20160; P80014; Q52LG4; Q9UCM1; Q9UCT5
• Molecular Weight: Molecular Mass: 25.2 kDa; Actual Protein Molecular Mass: 38 kDa
• NCBI Official Full Name: azurocidin preproprotein
• NCBI Official Synonym Full Names: azurocidin 1
• NCBI Official Symbol: AZU1
• NCBI Official Synonym Symbols: AZU; HBP; NAZC; hHBP; AZAMP; CAP37; HUMAZUR
• NCBI Protein Information: azurocidin
• UniProt Protein Name: Azurocidin
• UniProt Gene Name: AZU1
• UniProt Synonym Gene Names: HBP1 PublicationManual assertion based on opinion iniRef.7; hHBP1 PublicationManual assertion based on opinion iniRef.7

NCBI Description

Azurophil granules, specialized lysosomes of the neutrophil, contain at least 10 proteins implicated in the killing of microorganisms. This gene encodes a preproprotein that is proteolytically processed to generate a mature azurophil granule antibiotic protein, with monocyte chemotactic and antimicrobial activity. It is also an important multifunctional inflammatory mediator. This encoded protein is a member of the serine protease gene family but it is not a serine proteinase, because the active site serine and histidine residues are replaced. The genes encoding this protein, neutrophil elastase 2, and proteinase 3 are in a cluster located at chromosome 19pter. All 3 genes are expressed coordinately and their protein products are packaged together into azurophil granules during neutrophil differentiation. [provided by RefSeq, Nov 2015]

Uniprot Description

This is a neutrophil granule-derived antibacterial and monocyte- and fibroblast-specific chemotactic glycoprotein. Binds heparin. The cytotoxic action is limited to many species of Gram-negative bacteria; this specificity may be explained by a strong affinity of the very basic N-terminal half for the negatively charged lipopolysaccharides that are unique to the Gram-negative bacterial outer envelope. It may play a role in mediating recruitment of monocytes in the second wave of inflammation. Has antibacterial activity against the Gram-negative bacterium P.aeruginosa, this activity is inhibited by LPS from P.aeruginosa. Acting alone, it does not have antimicrobial activity against the Gram-negative bacteria A.actinomycetemcomitans ATCC 29532, A.actinomycetemcomitans NCTC 9709, A.actinomycetemcomitans FDC-Y4, H.aphrophilus ATCC 13252, E.corrodens ATCC 23834, C.sputigena ATCC 33123, Capnocytophaga sp ATCC 33124, Capnocytophaga sp ATCC 27872 or E.coli ML-35. Has antibacterial activity against C.sputigena ATCC 33123 when acting synergistically with either elastase or cathepsin G.